Thrombin Generation is Associated With CA 19-9 In Vitro and in Pancreatic Ductal Adenocarcinoma

被引：0
|
作者：
Mattila, N. [1 ,2 ,3 ]
Przybyla, B. [2 ,3 ]
Seppanen, H. [1 ,2 ]
Haglund, C. [1 ,2 ,4 ]
Lassila, R. [2 ,3 ,5 ]
机构：
[1] Univ Helsinki, Dept Surg, Helsinki, Finland
[2] Helsinki Univ Hosp, Helsinki, Finland
[3] Univ Helsinki, Dept Hematol, Coagulat Disorders Unit, Ctr Comprehens Canc, Helsinki, Finland
[4] Univ Helsinki, Res Programs Unit, Translat Canc Biol, Helsinki, Finland
[5] HUSLAB Lab Serv, Clin Chem, Helsinki, Finland
来源：
PANCREAS | 2018年 / 47卷 / 10期
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
引用
收藏
页码：1409 / 1409
页数：1
相关论文
共 50 条
  • [21] The Clinical Utility of CA 19-9 in Pancreatic Adenocarcinoma: Diagnostic and Prognostic Updates
    Poruk, K. E.
    Gay, D. Z.
    Brown, K.
    Mulvihill, J. D.
    Boucher, K. M.
    Scaife, C. L.
    Firpo, M. A.
    Mulvihill, S. J.
    CURRENT MOLECULAR MEDICINE, 2013, 13 (03) : 340 - 351
  • [22] Preoperative Panel of CA 19-9, Coagulation FVIII, Fibrin Turnover Marker D-Dimer, and Thrombin Time Predicts Postoperative Survival in Pancreatic Ductal Adenocarcinoma
    Mattila, N.
    Haglund, C.
    Lassila, R.
    Seppanen, H.
    PANCREAS, 2017, 46 (10) : 1418 - 1418
  • [23] Levels of the cancer biomarker CA 19-9 are associated with thrombin generation in plasma from treatment-na?ve pancreatic cancer patients
    Mattila, N.
    Hisada, Y.
    Przybyla, B.
    Posma, J.
    Jouppila, A.
    Haglund, C.
    Seppanen, H.
    Mackman, N.
    Lassila, R.
    THROMBOSIS RESEARCH, 2021, 199 : 21 - 31
  • [24] THE UTILITY OF CA 19-9 IN PATIENTS UNDERGOING EUS FOR PANCREATIC DUCTAL ADENOCARCINOMA: SINGLE CENTER EXPERIENCE OVER 2 DECADES
    Siddappa, Pradeep K.
    Chari, Suresh T.
    Gleeson, Ferga C.
    Malikowski, Tom
    Abu Dayyeh, Barham K.
    Chandrasekhara, Vinay
    Iyer, Prasad G.
    Majumder, Shounak
    Pearson, Randall K.
    Petersen, Bret T.
    Rajan, Elizabeth
    Storm, Andrew C.
    Topazian, Mark
    Vege, Santhi Swaroop
    Wang, Kenneth K.
    Levy, Michael J.
    GASTROENTEROLOGY, 2019, 156 (06) : S331 - S332
  • [25] CA 19-9 and pancreatic carcinoma, a revival?
    Ducreux, Michel
    Boige, Valerie
    Malka, David
    ONKOLOGIE, 2007, 30 (1-2): : 12 - 13
  • [26] Preoperative CA 19-9 Kinetics as a Prognostic Variable in Radiographically Resectable Pancreatic Adenocarcinoma
    Brown, E.
    Canter, R.
    Bold, R.
    ANNALS OF SURGICAL ONCOLOGY, 2014, 21 : S99 - S100
  • [27] CA 19-9 Response A Surrogate to Predict Survival in Patients With Metastatic Pancreatic Adenocarcinoma
    Diaz, Celso L.
    Cinar, Pelin
    Hwang, Jimmy
    Ko, Andrew H.
    Tempero, Margaret A.
    AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2019, 42 (12): : 898 - 902
  • [28] Prognostic impact of presurgical Ca 19-9 level in pancreatic adenocarcinoma: a pooled analysis
    Mattiucci, G. C.
    Arcelli, A.
    Bertini, F.
    Calvo, F. A.
    Falconi, M.
    Farioli, A.
    Guido, A.
    Frezza, G.
    Herman, J. M.
    Miller, R. C.
    Picardi, V.
    Macchia, G.
    Regine, W.
    Reni, M.
    Sharma, N.
    Morganti, A. G.
    Valentini, V.
    RADIOTHERAPY AND ONCOLOGY, 2016, 119 : S53 - S54
  • [29] Preoperative CA 19-9 Kinetics as a Prognostic Variable in Radiographically Resectable Pancreatic Adenocarcinoma
    Brown, Erin G.
    Canter, Robert J.
    Bold, Richard J.
    JOURNAL OF SURGICAL ONCOLOGY, 2015, 111 (03) : 293 - 298
  • [30] CA-125, but not galectin-3, complements CA 19-9 for discriminating ductal adenocarcinoma versus non-malignant pancreatic diseases
    Coppin, Lucie
    Benomar, Kanza
    Corfiotti, Francois
    Cattan, Stephane
    Renaud, Florence
    Lapere, Camille
    Leteurtre, Emmanuelle
    Vantyghem, Marie-Christine
    Truant, Stephanie
    Pigny, Pascal
    PANCREATOLOGY, 2016, 16 (01) : 115 - 120
12345